SCHEMBL23558952

SCHEMBL23558952

CSCc1ncc(C(C)C)s1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 6/20 0.38
CDK2 P24941 6/20 0.38
CDK5 Q00535 6/20 0.38
FDPS P14324 1/20 0.36
CCNT1 O60563 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CDK1 P06493 1/20 0.34
CDK4 P11802 1/20 0.34
CCNB1 P14635 1/20 0.34
CCNA2 P20248 1/20 0.34
CCND1 P24385 1/20 0.34
CDK7 P50613 1/20 0.34
CDK9 P50750 1/20 0.34
CCNH P51946 1/20 0.34
MNAT1 P51948 1/20 0.34
CDK5R1 Q15078 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SLC5A2 P31639 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2818339 0.78 CDK2 (0.41) CCNE1CDK2CDK5FDPSCCNT1
SCHEMBL18174959 0.76 CDK2 (0.40) CCNE1CDK2CDK5FDPSCCNT1
SCHEMBL13533948 0.74 CDK2 (0.39) CCNE1CDK2CDK5FDPSCCNT1
SCHEMBL24908094 0.74
SCHEMBL14425148 0.73 CCNE1 (0.38) CCNE1CDK2CDK5FDPSCCNT1
SCHEMBL12394764 0.73 CCNE1 (0.38) CCNE1CDK2CDK5FDPSCCNT1
SCHEMBL2593804 0.72
SCHEMBL19915568 0.71 CDK2 (0.46) CCNE1CDK2CDK5FDPSCCNT1
SCHEMBL2818612 0.70 ALDH1A1 (0.40) CCNE1CDK2CDK5FDPSCCNT1
SCHEMBL23208145 0.69 CCNE1 (0.50) CCNE1CDK2CDK5CCNT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-01-25 US disclosed
US-11873290-B2 2024-01-16 US disclosed
EP-4248973-A2 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2023-09-27 EP disclosed
EP-3877376-B1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2023-08-23 EP disclosed
WO-2021231615-A1 SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. (US) 2021-11-18 WO disclosed
US-11091464-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2021-08-17 US disclosed
US-20210188814-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188814-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A CCNE1 3734/4885CDK2 664/4885CDK5 141/4885
US-11873290-B2 IL6, MUSK, IL6ST CCNE1 4079/4885CDK2 675/4885CDK5 143/4885
US-11091464-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A CCNE1 3734/4885CDK2 664/4885CDK5 141/4885
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A CCNE1 3734/4885CDK2 664/4885CDK5 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.